NASDAQ:CORT - Corcept Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.60 +0.04 (+0.38 %)
(As of 05/21/2019 03:26 PM ET)
Previous Close$10.60
Today's Range$10.56 - $10.73
52-Week Range$9.14 - $20.00
Volume33,962 shs
Average Volume1.27 million shs
Market Capitalization$1.22 billion
P/E Ratio17.68
Dividend YieldN/A
Beta1.26
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$251.25 million
Cash Flow$0.6393 per share
Book Value$2.49 per share

Profitability

Net Income$75.41 million

Miscellaneous

Employees166
Market Cap$1.22 billion
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.18 by $0.03. The biotechnology company had revenue of $64.80 million for the quarter, compared to analysts' expectations of $69.29 million. Corcept Therapeutics had a net margin of 29.52% and a return on equity of 28.66%. Corcept Therapeutics's revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 EPS. View Corcept Therapeutics' Earnings History.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Corcept Therapeutics.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2019 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $285-315 million, compared to the consensus revenue estimate of $302.63 million.

What price target have analysts set for CORT?

3 Wall Street analysts have issued 1-year price objectives for Corcept Therapeutics' stock. Their forecasts range from $11.00 to $14.00. On average, they expect Corcept Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 13.2% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.

What is the consensus analysts' recommendation for Corcept Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corcept Therapeutics.

What are Wall Street analysts saying about Corcept Therapeutics stock?

Here are some recent quotes from research analysts about Corcept Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, "We have a N rating & a $14 PT for CORT based on our valuation of the Korlym + Rela’ franchise. We believe it’s about Rela’ and our question is when will it successfully complete the P3 in Cushing’s & displace Korlym? This thesis is our primary focus since it announced lower-than-projected Korlym rev for 4Q18 & 2019 guidance that points to limited upside potential (~20% midpoint of $285-315M)." (5/1/2019)
  • 2. According to Zacks Investment Research, "Corcept is making good progress with its Cushing's syndrome drug, Korlym. Notably, its efforts to expand Korlym’s label are encouraging and should boost the drug’s commercial potential significantly. The company is also making attempts to develop its pipeline with its most advanced candidate relacorilant (CORT125134), currently under evaluation in a phase II study for Cushing's syndrome. The successful development of its pipeline candidates will further boost the company’s portfolio and lead to increased sales. However, Corcept’s share price movement shows that the stock has underperformed the industry year to date. Moreover, Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will hinder the company’s growth prospects in the future quarters. Corcept has a positive record of earnings surprises in the recent quarters." (4/30/2019)

Has Corcept Therapeutics been receiving favorable news coverage?

Media coverage about CORT stock has been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Corcept Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Corcept Therapeutics' key competitors?

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), CA (CA), BlackRock (BLK), NVIDIA (NVDA), Alibaba Group (BABA), Endologix (ELGX), Celgene (CELG), AbbVie (ABBV), Advanced Micro Devices (AMD) and YY (YY).

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the folowing people:
  • Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)
  • Mr. Gary Charles Robb, CFO & Sec. (Age 56)
  • Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
  • Dr. Christopher Shayne James M.D., Director of Investor Relations
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.80%), Federated Investors Inc. PA (9.73%), Ingalls & Snyder LLC (7.30%), Renaissance Technologies LLC (4.40%), Dimensional Fund Advisors LP (2.01%) and Northern Trust Corp (1.12%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics.

Which major investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Federated Investors Inc. PA, Marshall Wace LLP, PNC Financial Services Group Inc., Wells Fargo & Company MN, SG Americas Securities LLC, Catalyst Capital Advisors LLC and Raymond James & Associates. Company insiders that have sold Corcept Therapeutics company stock in the last year include Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck. View Insider Buying and Selling for Corcept Therapeutics.

Which major investors are buying Corcept Therapeutics stock?

CORT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, BlackRock Inc., Acadian Asset Management LLC, FMR LLC, First Trust Advisors LP, Man Group plc and JPMorgan Chase & Co.. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $10.60.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $1.22 billion and generates $251.25 million in revenue each year. The biotechnology company earns $75.41 million in net income (profit) each year or $0.60 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is http://www.corcept.com.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  322 (Vote Underperform)
Total Votes:  714
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel